NCT01560325View on ClinicalTrials.gov

Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

CKD-516 inj.

CKD-516: 3.3\~13mg/m2/day

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY